Occurrence of hepatoxicicty and elevated liver enzymes in a Crohn's disease patient treated with infliximab
β Scribed by B. Moum; Z. Konopski; K.F. Tufteland; J. Jahnsen
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 100 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
2004 we reported 3 cases of chronic hepatitis B in Crohn's disease (CD) patients from a cohort of 80 patients treated with infliximab. 1 Two patients showed severe reactivation, 1 of whom died. Based on the American Association for the Study of Liver Disease (AASLD) and European guidelines, 2,3 pree
Background: Under experimental chronic inflammation, tumor necrosis factor (TNF)-β£ plays a role in damaging spleen marginal zone. This latter has a crucial function in mounting B cell-dependent immune responses against infections by encapsulated bacteria. In Crohn's disease (CD), a chronic inflammat
## Background: The long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term. Methods: A multic
The authors thank D. Dehay (CH Valenciennes) for expert technical assistance, BioCytex Co. for providing reagents, V. Deken (Centre d'Etude et de Recherche en Informatique Me Β΄dicale, CHRU Lille), and INSERM U795 for their contribution to statistical analysis.